Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Jayappa, Kallesh D., Portell, Craig A., Gordon, Vicki L., Capaldo, Brian J., Bekiranov, Stefan, Axelrod, Mark J., Brett, L. Kyle, Wulfkuhle, Julia D., Gallagher, Rosa I., Petricoin, Emanuel F., Bender, Timothy P., Williams, Michael E., Weber, Michael J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2017
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637393/
https://ncbi.nlm.nih.gov/pubmed/29034364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016004176
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia